reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

Mental health care for all, no prescription necessary.

Our digital therapeutics are safe and effective non-drug alternatives for mental health.

Mental health care for all, no prescription necessary.

Our digital therapeutics are safe and effective non-drug alternatives for mental health.

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.

We’re committed to gold-standard clinical evidence. We have over 70 peer-reviewed publications with more than 28,000 participants, including more than 13 randomized controlled trials (RCTs).